logo

Retrophin Inc. (RTRX)



Trade RTRX now with
  Date
  Headline
8/22/2019 6:04:01 AM Retrophin Says FORT Study Did Not Achieve Its Primary Or Secondary Endpoints
5/13/2019 8:06:21 AM Retrophin Appoints Sandra Poole To Board
1/7/2019 7:20:01 AM Retrophin Expects Net Product Sales For Q4 To Be $44 Mln
1/3/2019 5:16:25 PM Retrophin Names Eric Dube President And CEO
12/20/2018 8:08:13 AM Retrophin Completes Enrollment Of Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN
11/12/2018 7:02:51 AM Retrophin Announces FDA Acceptance Of NDA Filing For New Formulation Of Thiola For Cystinuria
7/30/2018 4:34:26 PM Retrophin Appoints Noah Rosenberg As Chief Medical Officer
6/4/2018 8:11:02 AM Retrophin Announces Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN Opens Enrollment To Pediatric Patients
4/3/2018 8:14:53 AM Retrophin Begins Pivotal Phase 3 Clinical Trial Of Sparsentan For Treatment Of Focal Segmental Glomerulosclerosis
3/5/2018 4:33:09 PM Retrophin Appoints Casey Logan As VP Of Corporate Development
1/8/2018 7:18:28 AM Retrophin Expects Net Product Sales For Q4 To Be $42 Mln
4/6/2017 7:10:50 AM William Blair Starts Retrophin Inc. (RTRX) At Outperform
5/12/2015 12:29:20 PM Deutsche Bank Reiterates Retrophin Inc. (RTRX) At Buy With $50 Price Target
4/28/2015 12:19:47 PM Deutsche Bank Initiates Retrophin Inc. (RTRX) At Buy With $50 Price Target
  
 
>